Sandbox:Cancer screening and primary care: Difference between revisions
No edit summary |
|||
Line 1: | Line 1: | ||
{{CMG}}{{AE}}{{VD}} | |||
==Overview== | ==Overview== | ||
World wide, cancer is among the leading causes of [[morbidity]] and [[mortality]], contributing to approximately 8.2 million deaths in 2012, with an estimated 13% of overall deaths.<ref name=":0">http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx</ref> [[World Health Organization|WHO]] expects a 70% increase in number of new cases over the next 2 decades.<ref>http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx</ref> The burden of [[cancer]] is substantial and increasing worldwide.<ref name="pmid26667886">{{cite journal| author=Torre LA, Siegel RL, Ward EM, Jemal A| title=Global Cancer Incidence and Mortality Rates and Trends--An Update. | journal=Cancer Epidemiol Biomarkers Prev | year= 2016 | volume= 25 | issue= 1 | pages= 16-27 | pmid=26667886 | doi=10.1158/1055-9965.EPI-15-0578 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26667886 }}</ref> The [[incidence]], [[prevalence]] and [[mortality]] of a specific cancer varies widely across countries. This variability is attributable to variations in lifestyle risk factors ([[tobacco]] use, physical inactivity, excess body weight, reproductive patterns), prevalence of [[Carcinogenic|carcinogenic infections]]([[Hepatitis B]], [[Hepatitis C]] and [[HPV]]), [[genetics]], and availability of health care resources.<ref name="pmid26667886" /> In 2012, [[Lung cancer|lung]], [[Prostate cancer|prostate]], [[Colorectal cancer|colorectal]], [[Gastric Cancer|gastric]], and [[Liver Cancer|liver]] carcinomas were the most common cancers among men while [[Breast cancer|breast]], [[Colorectal Cancer|colorectal]], [[Lung Cancer|lung]], [[Cervical cancer|cervical]], and [[Stomach cancer|gastric carcinomas]] were common among women.<ref>{{Cite web|url=https://www.cdc.gov/cancer/international/statistics.htm|title=Cdc|last=|first=|date=|website=|publisher=|access-date=}}</ref> In 2014, Agency for healthcare research and Quality has estimated that the direct medical cost for cancer in United states were at $87.7 billion dollars.<ref>{{Cite web|url=https://cdn-stage.ahrq.gov/research/data/index.html|title=Agency of health research and quality|last=|first=|date=|website=|publisher=|access-date=}}</ref>It is estimated that [[HBV]]/[[HCV]] and [[HPV]] are responsible for up to 20% of cancer deaths in low and middle-income countries. It is also estimated that more then 30% of the cases can be prevented. Measures to prevent some types of cancer include effective [[screening]], [[vaccination]], and lifestyle modifications. In this page we discussed the [[epidemiology]] and [[primary care]] aspects in preventing [[cancer]]. | World wide, cancer is among the leading causes of [[morbidity]] and [[mortality]], contributing to approximately 8.2 million deaths in 2012, with an estimated 13% of overall deaths.<ref name=":0">http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx</ref> [[World Health Organization|WHO]] expects a 70% increase in number of new cases over the next 2 decades.<ref>http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx</ref> The burden of [[cancer]] is substantial and increasing worldwide.<ref name="pmid26667886">{{cite journal| author=Torre LA, Siegel RL, Ward EM, Jemal A| title=Global Cancer Incidence and Mortality Rates and Trends--An Update. | journal=Cancer Epidemiol Biomarkers Prev | year= 2016 | volume= 25 | issue= 1 | pages= 16-27 | pmid=26667886 | doi=10.1158/1055-9965.EPI-15-0578 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26667886 }}</ref> The [[incidence]], [[prevalence]] and [[mortality]] of a specific cancer varies widely across countries. This variability is attributable to variations in lifestyle risk factors ([[tobacco]] use, physical inactivity, excess body weight, reproductive patterns), prevalence of [[Carcinogenic|carcinogenic infections]]([[Hepatitis B]], [[Hepatitis C]] and [[HPV]]), [[genetics]], and availability of health care resources.<ref name="pmid26667886" /> In 2012, [[Lung cancer|lung]], [[Prostate cancer|prostate]], [[Colorectal cancer|colorectal]], [[Gastric Cancer|gastric]], and [[Liver Cancer|liver]] carcinomas were the most common cancers among men while [[Breast cancer|breast]], [[Colorectal Cancer|colorectal]], [[Lung Cancer|lung]], [[Cervical cancer|cervical]], and [[Stomach cancer|gastric carcinomas]] were common among women.<ref>{{Cite web|url=https://www.cdc.gov/cancer/international/statistics.htm|title=Cdc|last=|first=|date=|website=|publisher=|access-date=}}</ref> In 2014, Agency for healthcare research and Quality has estimated that the direct medical cost for cancer in United states were at $87.7 billion dollars.<ref>{{Cite web|url=https://cdn-stage.ahrq.gov/research/data/index.html|title=Agency of health research and quality|last=|first=|date=|website=|publisher=|access-date=}}</ref>It is estimated that [[HBV]]/[[HCV]] and [[HPV]] are responsible for up to 20% of cancer deaths in low and middle-income countries. It is also estimated that more then 30% of the cases can be prevented. Measures to prevent some types of cancer include effective [[screening]], [[vaccination]], and lifestyle modifications. In this page we discussed the [[epidemiology]] and [[primary care]] aspects in preventing [[cancer]]. | ||
==Epidemiology== | ==Epidemiology== | ||
World wide, cancer is among the leading causes of [[morbidity]] and [[mortality]], contributing to approximately 8.2 million deaths in 2012, with an estimated 13% of overall deaths.<ref name=":0" /> The most common type of cancer, excluding non-melanoma skin cancers is breast cancer, with more than 249,000 new cases expected in the United States in 2016. The next most common cancers | World wide, cancer is among the leading causes of [[morbidity]] and [[mortality]], contributing to approximately 8.2 million deaths in 2012, with an estimated 13% of overall deaths.<ref name=":0" /> The most common type of cancer, excluding [[Skin cancer|non-melanoma skin cancers]] is [[breast cancer]], with more than 249,000 new cases expected in the United States in 2016. The next most common cancers are [[lung cancer]] and [[prostate cancer]]. In United states, to qualify as a common cancer, the estimated annual incidence for 2016 had to be 40,000 cases or more. | ||
The following table gives the estimated numbers of new cases and deaths in Unites states for each common cancer type: <ref>American Cancer Society. Cancer Facts & Figures 2016. Atlanta: American Cancer Society; 2016</ref> | The following table gives the estimated numbers of new cases and deaths in Unites states for each common cancer type: <ref>American Cancer Society. Cancer Facts & Figures 2016. Atlanta: American Cancer Society; 2016</ref> | ||
Line 162: | Line 164: | ||
===Childhood Cancers=== | ===Childhood Cancers=== | ||
In 2013, the most commonly diagnosed cancers and leading causes of cancer death in children aged 0 to 19 years were Leukemia's and Central nervous system cancers.<ref>{{Cite web|url=www.cdc.gov/uscs.|title=U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2013 Incidence and Mortality Web-based Report. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2016.|last=|first=|date=|website=|publisher=|access-date=}}</ref> | In 2013, the most commonly diagnosed cancers and leading causes of cancer death in children aged 0 to 19 years were [[Leukemia|Leukemia's]] and [[Central nervous system tumors|Central nervous system cancers]].<ref>{{Cite web|url=www.cdc.gov/uscs.|title=U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2013 Incidence and Mortality Web-based Report. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2016.|last=|first=|date=|website=|publisher=|access-date=}}</ref> | ||
{| class="wikitable" | {| class="wikitable" | ||
Line 189: | Line 191: | ||
|0.6 | |0.6 | ||
|- | |- | ||
|Brain and Central nervous system cancer | |[[Central nervous system tumors|Brain and Central nervous system cancer]] | ||
|3.6 | |3.6 | ||
|3.2 | |3.2 | ||
Line 214: | Line 216: | ||
|- | |- | ||
|Women, 40 Years and Older | |Women, 40 Years and Older | ||
|The USPSTF concludes that the current evidence is insufficient to assess the additional benefits and harms of clinical breast examination (CBE) beyond screening mammography in women 40 years or older. | |The [[United states preventive services task force recommendations scheme|USPSTF]] concludes that the current evidence is insufficient to assess the additional benefits and harms of [[Breast examination|clinical breast examination (CBE)]] beyond screening [[mammography]] in women 40 years or older. | ||
|[[USPSTF guidelines classification scheme|'''I''']] | |[[USPSTF guidelines classification scheme|'''I''']] | ||
|- | |- | ||
|Women, Age 50-74 Years | |Women, Age 50-74 Years | ||
|The USPSTF recommends biennial screening mammography for women 50-74 years. | |The [[United states preventive services task force recommendations scheme|USPSTF]] recommends biennial screening [[mammography]] for women 50-74 years. | ||
|'''[[USPSTF guidelines classification scheme|B]]''' | |'''[[USPSTF guidelines classification scheme|B]]''' | ||
|- | |- | ||
|Women, Before the Age of 50 Years | |Women, Before the Age of 50 Years | ||
|The decision to start regular, biennial screening mammography before the age of 50 years should be an individual one and take patient context into account, including the patient's values regarding specific benefits and harms. | |The decision to start regular, biennial screening [[mammography]] before the age of 50 years should be an individual one and take patient context into account, including the patient's values regarding specific benefits and harms. | ||
|[[USPSTF guidelines classification scheme|'''C''']] | |[[USPSTF guidelines classification scheme|'''C''']] | ||
|- | |- | ||
|Women, 75 Years and Older | |Women, 75 Years and Older | ||
|The USPSTF concludes that the current evidence is insufficient to assess the benefits and harms of screening mammography in women 75 years and older. | |The [[USPSTF]] concludes that the current evidence is insufficient to assess the benefits and harms of screening [[mammography]] in women 75 years and older. | ||
|[[USPSTF guidelines classification scheme|'''I''']] | |[[USPSTF guidelines classification scheme|'''I''']] | ||
|} | |} | ||
====Breast cancer screening relevance==== | ====Breast cancer screening relevance==== | ||
Studies have reported that, for women of all age groups with an average risk, ''breast screening'' was associated with a reduction in breast cancer mortality of approximately 20%, although there was an uncertainty in the quantitative estimates of outcomes for different breast cancer screening strategies in the United States.<ref name="pmid26501537222">{{cite journal| author=Myers ER, Moorman P, Gierisch JM, Havrilesky LJ, Grimm LJ, Ghate S et al.| title=Benefits and Harms of Breast Cancer Screening: A Systematic Review. | journal=JAMA | year= 2015 | volume= 314 | issue= 15 | pages= 1615-34 | pmid=26501537 | doi=10.1001/jama.2015.13183 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26501537 }} [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26974726 Review in: Ann Intern Med. 2016 Mar 15;164(6):JC26]</ref> | Studies have reported that, for women of all age groups with an average risk, ''[[breast cancer screening]]'' was associated with a reduction in [[Breast cancer epidemiology and demographics|breast cancer mortality]] of approximately 20%, although there was an uncertainty in the quantitative estimates of outcomes for different breast cancer screening strategies in the United States.<ref name="pmid26501537222">{{cite journal| author=Myers ER, Moorman P, Gierisch JM, Havrilesky LJ, Grimm LJ, Ghate S et al.| title=Benefits and Harms of Breast Cancer Screening: A Systematic Review. | journal=JAMA | year= 2015 | volume= 314 | issue= 15 | pages= 1615-34 | pmid=26501537 | doi=10.1001/jama.2015.13183 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26501537 }} [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26974726 Review in: Ann Intern Med. 2016 Mar 15;164(6):JC26]</ref> | ||
'''Please [[Breast cancer screening|click here]] to know more about ''[[breast cancer screening]]''''' | '''Please [[Breast cancer screening|click here]] to know more about ''[[breast cancer screening]]''''' | ||
Line 242: | Line 244: | ||
|- | |- | ||
|Adults aged 50 to 75 years | |Adults aged 50 to 75 years | ||
|The USPSTF recommends screening for colorectal cancer starting at age 50 years and continuing until age 75 years. | |The [[USPSTF]] recommends screening for [[colorectal cancer]] starting at age 50 years and continuing until age 75 years. | ||
|'''[[USPSTF guidelines classification scheme|A]]''' | |'''[[USPSTF guidelines classification scheme|A]]''' | ||
|- | |- | ||
|Adults aged 76 to 85 years | |Adults aged 76 to 85 years | ||
|The decision to screen for colorectal cancer in adults aged 76 to 85 years should be an individual one, taking into account the patient’s overall health and prior screening history. | |The decision to screen for [[colorectal cancer]] in adults aged 76 to 85 years should be an individual one, taking into account the patient’s overall health and prior screening history. | ||
*Adults in this age group who have never been screened for colorectal cancer are more likely to benefit. | *Adults in this age group who have never been screened for [[colorectal cancer]] are more likely to benefit. | ||
*Screening would be most appropriate among adults who 1) are healthy enough to undergo treatment if colorectal cancer is detected and 2) do not have | *Screening would be most appropriate among adults who 1) are healthy enough to undergo treatment if [[colorectal cancer]] is detected and 2) do not have co-morbid conditions that would significantly limit their life expectancy. | ||
|'''[[USPSTF guidelines classification scheme|C]]''' | |'''[[USPSTF guidelines classification scheme|C]]''' | ||
|}'''Colon cancer screening relevance''' | |}'''Colon cancer screening relevance''' | ||
Studies have reported, 40% to 60% lower risk of incident colorectal cancer and mortality from colorectal cancer after screening colonoscopy.<ref name="pmid2492274522">{{cite journal| author=Brenner H, Stock C, Hoffmeister M| title=Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. | journal=BMJ | year= 2014 | volume= 348 | issue= | pages= g2467 | pmid=24922745 | doi=10.1136/bmj.g2467 | pmc=3980789 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24922745 }}</ref> | Studies have reported, 40% to 60% lower risk of incident [[colorectal cancer]] and [[mortality]] from [[colorectal cancer]] after [[Colonoscopy|screening colonoscopy]].<ref name="pmid2492274522">{{cite journal| author=Brenner H, Stock C, Hoffmeister M| title=Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. | journal=BMJ | year= 2014 | volume= 348 | issue= | pages= g2467 | pmid=24922745 | doi=10.1136/bmj.g2467 | pmc=3980789 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24922745 }}</ref> | ||
'''Please [[Colorectal cancer screening|click here]] to know more about [[Colorectal cancer screening|''Colon cancer screening'']]''.''''' | '''Please [[Colorectal cancer screening|click here]] to know more about [[Colorectal cancer screening|''Colon cancer screening'']]''.''''' | ||
Line 263: | Line 265: | ||
|'''[[USPSTF guidelines classification scheme|Grade]]''' | |'''[[USPSTF guidelines classification scheme|Grade]]''' | ||
|- | |- | ||
|Women 21 to 65 (Pap Smear) or 30-65 (in combo with HPV testing) | |Women 21 to 65 ([[Pap smear|Pap Smear]]) or 30-65 (in combo with [[HPV]] testing) | ||
|The USPSTF recommends screening for cervical cancer in women age 21 to 65 years with cytology (Pap smear) every 3 years or, for women age 30 to 65 years who want to lengthen the screening interval, screening with a combination of cytology and human papillomavirus (HPV) testing every 5 years. | |The [[USPSTF]] recommends screening for cervical cancer in women age 21 to 65 years with [[cytology]] ([[Pap smear]]) every 3 years or, for women age 30 to 65 years who want to lengthen the screening interval, screening with a combination of [[cytology]] and [[human papillomavirus]] (HPV) testing every 5 years. | ||
|'''[[USPSTF guidelines classification scheme|A]]''' | |'''[[USPSTF guidelines classification scheme|A]]''' | ||
|}'''Cervical cancer screening relevance''' | |}'''Cervical cancer screening relevance''' | ||
Studies have reported, that in patients undergoing regular cervical cancer, approximately 70%-80% of cervical cancer deaths can be prevented.<ref name="pmid276323762">{{cite journal| author=Landy R, Pesola F, Castañón A, Sasieni P| title=Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested case-control study. | journal=Br J Cancer | year= 2016 | volume= 115 | issue= 9 | pages= 1140-1146 | pmid=27632376 | doi=10.1038/bjc.2016.290 | pmc=5117785 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27632376 }}</ref> | Studies have reported, that in patients undergoing regular [[cervical cancer]], approximately 70%-80% of [[cervical cancer]] deaths can be prevented.<ref name="pmid276323762">{{cite journal| author=Landy R, Pesola F, Castañón A, Sasieni P| title=Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested case-control study. | journal=Br J Cancer | year= 2016 | volume= 115 | issue= 9 | pages= 1140-1146 | pmid=27632376 | doi=10.1038/bjc.2016.290 | pmc=5117785 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27632376 }}</ref> | ||
'''Please [[Cervical cancer screening|click here]] to know more about [[Cervical cancer screening|''Cervical cancer screening'']]''.''''' | '''Please [[Cervical cancer screening|click here]] to know more about [[Cervical cancer screening|''Cervical cancer screening'']]''.''''' | ||
Line 280: | Line 282: | ||
|- | |- | ||
|Adults Aged 55-80, with a History of Smoking | |Adults Aged 55-80, with a History of Smoking | ||
|The USPSTF recommends annual screening for lung cancer with low-dose computed tomography (LDCT) in adults aged 55 to 80 years who have a 30 pack-year smoking history and currently smoke or have quit within the past 15 years. Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery. | |The [[USPSTF]] recommends annual screening for [[lung cancer]] with [[Computed tomography|low-dose computed tomography]] (LDCT) in adults aged 55 to 80 years who have a 30 pack-year smoking history and currently smoke or have quit within the past 15 years. [[Screening]] should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery. | ||
|'''[[USPSTF guidelines classification scheme|B]]''' | |'''[[USPSTF guidelines classification scheme|B]]''' | ||
|}'''Lung caner screening relevance''' | |}'''Lung caner screening relevance''' | ||
Line 294: | Line 296: | ||
| rowspan="2" |[[HPV Vaccine|HPV vaccine]] | | rowspan="2" |[[HPV Vaccine|HPV vaccine]] | ||
|Age< 15 years | |Age< 15 years | ||
|Two doses of HPV vaccine at least six months apart. | |Two doses of [[HPV Vaccine|HPV vaccine]] at least six months apart. | ||
|- | |- | ||
|Age> 15 years | |Age> 15 years | ||
| | | | ||
*Three doses of HPV vaccine over a span of 24 weeks, with a minimum of 4 weeks interval between the first two doses, and 12 weeks between second and third dose. | *Three doses of [[HPV vaccine]] over a span of 24 weeks, with a minimum of 4 weeks interval between the first two doses, and 12 weeks between second and third dose. | ||
*Young women can get HPV vaccine until they are 27 years old and young men can get HPV vaccine until they are 22 years old. | *Young women can get [[HPV Vaccine|HPV vaccine]] until they are 27 years old and young men can get [[HPV vaccine]] until they are 22 years old. | ||
|- | |- | ||
|[[Hepatitis B vaccine]] | |[[Hepatitis B vaccine]] | ||
| colspan="2" | | | colspan="2" | | ||
*All infants should receive their first dose of hepatitis B vaccine as soon as possible after birth, preferably within 24 hours, followed by two or three additional doses. | *All infants should receive their first dose of [[hepatitis B vaccine]] as soon as possible after birth, preferably within 24 hours, followed by two or three additional doses. | ||
*The vaccination schedule for children and adults involves | *The [[vaccination]] schedule for children and adults involves 3 [[Intramuscular injection|intramuscular injections]], the second and third doses administered 1 and 6 months after the first. | ||
|}'''HPV vaccine relevance in cancer prevention''' | |}'''HPV vaccine relevance in cancer prevention''' | ||
Studies have reported, that introduction of the 4vHPV vaccine, has decreased the prevalence of HPV 6/11/16/18 cervical/vaginal infections, genital warts, low- and high-grade cytological abnormalities, CIN2, CIN3, and AIS among females in their teens and 20s.<ref name="pmid27230391">{{cite journal| author=Garland SM, Kjaer SK, Muñoz N, Block SL, Brown DR, DiNubile MJ et al.| title=Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience. | journal=Clin Infect Dis | year= 2016 | volume= 63 | issue= 4 | pages= 519-27 | pmid=27230391 | doi=10.1093/cid/ciw354 | pmc=4967609 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27230391 }}</ref> | Studies have reported, that introduction of the 4vHPV vaccine, has decreased the prevalence of [[HPV|HPV 6/11/16/18]] cervical/vaginal infections, [[genital warts]], low- and high-grade cytological abnormalities, [[CIN|CIN2]], CIN3, and [[AIS]] among females in their teens and 20s.<ref name="pmid27230391">{{cite journal| author=Garland SM, Kjaer SK, Muñoz N, Block SL, Brown DR, DiNubile MJ et al.| title=Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience. | journal=Clin Infect Dis | year= 2016 | volume= 63 | issue= 4 | pages= 519-27 | pmid=27230391 | doi=10.1093/cid/ciw354 | pmc=4967609 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27230391 }}</ref> | ||
'''Please [[HPV vaccine|click here]] for know more about [[HPV Vaccine|''HPV vaccine'']]''.''''' | '''Please [[HPV vaccine|click here]] for know more about [[HPV Vaccine|''HPV vaccine'']]''.''''' | ||
Line 313: | Line 315: | ||
'''Hepatitis B vaccine relevance in cancer prevention''' | '''Hepatitis B vaccine relevance in cancer prevention''' | ||
Strong evidence that hepatocellular cancer (HCC) can be prevented is provided by a cluster randomized controlled trial of the immunization of 75,000 newborns with hepatitis B virus (HBV) vaccine. After a median of about 25 years of follow-up, the incidence ratio of primary liver cancer in the vaccination-at-birth group to the control group (68% of whom received catch-up vaccinations at ages 10–14 years) was 0.16 (95% confidence interval, 0.03–0.77).<ref name="pmid25549238">{{cite journal| author=Qu C, Chen T, Fan C, Zhan Q, Wang Y, Lu J et al.| title=Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: a cluster randomized controlled trial. | journal=PLoS Med | year= 2014 | volume= 11 | issue= 12 | pages= e1001774 | pmid=25549238 | doi=10.1371/journal.pmed.1001774 | pmc=4280122 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25549238 }}</ref> These findings suggest that if HBV can be prevented, then much HCC can be prevented. | Strong evidence that [[Hepatocellular Carcinoma|hepatocellular cancer (HCC)]] can be prevented is provided by a cluster [[randomized controlled trial]] of the [[immunization]] of 75,000 newborns with [[hepatitis B virus]] (HBV) vaccine. After a [[median]] of about 25 years of follow-up, the incidence ratio of [[Liver tumor|primary liver cancer]] in the vaccination-at-birth group to the control group (68% of whom received catch-up vaccinations at ages 10–14 years) was 0.16 (95% [[confidence interval]], 0.03–0.77).<ref name="pmid25549238">{{cite journal| author=Qu C, Chen T, Fan C, Zhan Q, Wang Y, Lu J et al.| title=Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: a cluster randomized controlled trial. | journal=PLoS Med | year= 2014 | volume= 11 | issue= 12 | pages= e1001774 | pmid=25549238 | doi=10.1371/journal.pmed.1001774 | pmc=4280122 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25549238 }}</ref> These findings suggest that if [[HBV]] can be prevented, then much [[Hepatocellular carcinoma|HCC]] can be prevented. | ||
'''Please [[Hepatitis B vaccine|click here]] for know more about [[Hepatitis B vaccine|''Hepatitis B vaccine'']]''.''''' | '''Please [[Hepatitis B vaccine|click here]] for know more about [[Hepatitis B vaccine|''Hepatitis B vaccine'']]''.''''' | ||
Line 321: | Line 323: | ||
|- | |- | ||
| rowspan="2" |'''Avoiding Tobacco''' | | rowspan="2" |'''Avoiding Tobacco''' | ||
|Cigarette Smoking | |[[Smoking|Cigarette Smoking]] | ||
|Lung cancer is the leading cause of cancer death, and cigarette smoking causes almost all cases. Compared to nonsmokers, current smokers are about 25 times more likely to die from lung cancer. Smoking causes about 80% to 90% of lung cancer deaths. Smoking also causes cancer of the mouth and throat, esophagus, stomach, colon, rectum, liver, pancreas, voicebox (larynx), trachea, bronchus, kidney and renal pelvis, urinary bladder, and cervix, and causes acute myeloid leukemia.<ref>{{Cite web|url=https://www.surgeongeneral.gov/library/reports/50-years-of-progress/|title=U.S. Department of Health and Human Services. The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General, 2014.|date=|access-date=|website=|publisher=|last=|first=}}</ref><ref>{{Cite web|url=http://monographs.iarc.fr/ENG/Monographs/vol100E/|title=International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans: Volume 100E: Personal Habits and Indoor Combustions. Lyon, France: International Agency for Research on Cancer; 2012.|last=|first=|date=|website=|publisher=|access-date=}}</ref> | |[[Lung cancer]] is the leading cause of cancer death, and cigarette smoking causes almost all cases. Compared to nonsmokers, current smokers are about 25 times more likely to die from lung cancer. Smoking causes about 80% to 90% of lung cancer deaths. Smoking also causes cancer of the mouth and throat, [[Oesophageal carcinoma|esophagus]], [[Stomach cancer|stomach]], [[Colon cancer|colon]], [[Rectal Cancer|rectum]], [[Liver Cancer|liver]], [[Pancreas cancer|pancreas]], [[Laryngeal cancer|voicebox]] ([[Larynx Carcinoma|larynx]]), [[trachea]], [[bronchus]], [[Renal cell carcinoma|kidney and renal pelvis]], [[Urinary bladder cancer|urinary bladder]], and [[Cervical cancer causes|cervix]], and causes [[acute myeloid leukemia]].<ref>{{Cite web|url=https://www.surgeongeneral.gov/library/reports/50-years-of-progress/|title=U.S. Department of Health and Human Services. The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General, 2014.|date=|access-date=|website=|publisher=|last=|first=}}</ref><ref>{{Cite web|url=http://monographs.iarc.fr/ENG/Monographs/vol100E/|title=International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans: Volume 100E: Personal Habits and Indoor Combustions. Lyon, France: International Agency for Research on Cancer; 2012.|last=|first=|date=|website=|publisher=|access-date=}}</ref> | ||
|- | |- | ||
|Secondhand Smoke | |Secondhand Smoke | ||
|Adults who are exposed to secondhand smoke at home or at work increase their risk of developing lung cancer by 20% to 30%. Concentrations of many cancer-causing and toxic chemicals are higher in secondhand smoke than in the smoke inhaled by smokers. | |Adults who are exposed to secondhand smoke at home or at work increase their risk of developing [[lung cancer]] by 20% to 30%. Concentrations of many cancer-causing and toxic chemicals are higher in secondhand smoke than in the smoke inhaled by smokers. | ||
'''Please [[Smoking cessation|click here]] to know more about [[smoking cessation]]''' | '''Please [[Smoking cessation|click here]] to know more about [[smoking cessation]]''' | ||
'''Please [[Lung cancer|click here]] to know more about [[Lung cancer]]''' | |||
|- | |- | ||
| colspan="2" |'''Protecting Your Skin''' | | colspan="2" |'''Protecting Your Skin''' | ||
|Skin cancer is the most common kind of cancer in the United States. Exposure to ultraviolet (UV) rays from the sun and tanning beds appears to be the most important environmental factor involved with developing skin cancer. To help prevent skin cancer while still having fun outdoors, protect yourself by seeking shade, applying sunscreen, and wearing sun-protective clothing, a hat, and sunglasses. | |[[Skin cancer]] is the most common kind of cancer in the United States. Exposure to [[Ultraviolet|ultraviolet (UV) rays]] from the sun and tanning beds appears to be the most important environmental factor involved with developing skin cancer. To help prevent [[skin cancer]] while still having fun outdoors, protect yourself by seeking shade, applying sunscreen, and wearing sun-protective clothing, a hat, and sunglasses. | ||
'''Please [[Skin cancer|click here]] to know more about [[Skin cancer]]''' | '''Please [[Skin cancer|click here]] to know more about [[Skin cancer]]''' | ||
Line 335: | Line 339: | ||
| colspan="2" |'''Limiting Alcohol Intake''' | | colspan="2" |'''Limiting Alcohol Intake''' | ||
| | | | ||
* Studies around the world have shown that drinking alcohol regularly increases the risk of getting mouth, voice box, and throat cancers. | * Studies around the world have shown that drinking alcohol regularly increases the risk of getting [[mouth]], [[voice box]], and [[Throat|throat cancers]]. | ||
* A large number of studies provide strong evidence that drinking alcohol is a risk factor for primary liver cancer, and more than 100 studies have found an increased risk of breast cancer with increasing alcohol intake. The link between alcohol consumption and colorectal (colon) cancer has been reported in more than 50 studies.<ref name="pmid17431955">{{cite journal| author=Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Bouvard V et al.| title=Carcinogenicity of alcoholic beverages. | journal=Lancet Oncol | year= 2007 | volume= 8 | issue= 4 | pages= 292-3 | pmid=17431955 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17431955 }}</ref> | * A large number of studies provide strong evidence that drinking alcohol is a risk factor for [[Hepatocellular carcinoma|primary liver cancer]], and more than 100 studies have found an increased risk of [[breast cancer]] with increasing alcohol intake. The link between alcohol consumption and [[Colorectal Cancer|colorectal (colon) cancer]] has been reported in more than 50 studies.<ref name="pmid17431955">{{cite journal| author=Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Bouvard V et al.| title=Carcinogenicity of alcoholic beverages. | journal=Lancet Oncol | year= 2007 | volume= 8 | issue= 4 | pages= 292-3 | pmid=17431955 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17431955 }}</ref> | ||
'''Please [[Alcholism|click here]] to know more about [[alcoholism]]''' | '''Please [[Alcholism|click here]] to know more about [[alcoholism]]''' | ||
|- | |- | ||
| colspan="2" |'''Keeping a Healthy Weight''' | | colspan="2" |'''Keeping a Healthy Weight''' | ||
|Research has shown that being overweight or obese substantially raises a person’s risk of getting endometrial (uterine), breast, prostate, and colorectal cancers. Overweight is defined as a body mass index (BMI) of 25 to 29, and obesity is defined as a BMI of 30 or higher. | |Research has shown that being [[overweight]] or [[Obesity|obese]] substantially raises a person’s risk of getting [[Endometrial cancer|endometrial (uterine)]], [[Breast cancer|breast]], [[Prostate cancer|prostate]], and [[Colorectal cancer|colorectal cancers]]. [[Overweight]] is defined as a [[Body mass index|body mass index (BMI)]] of 25 to 29, and obesity is defined as a [[BMI]] of 30 or higher. | ||
'''Please [[Obesity|click here]] to know more about ''[[Obesity|obesity management]]''''' | '''Please [[Obesity|click here]] to know more about ''[[Obesity|obesity management]]''''' | ||
|- | |- | ||
| colspan="2" |'''Getting Tested for Hepatitis C''' | | colspan="2" |'''Getting Tested for Hepatitis C''' | ||
|''Hepatitis'' is inflammation of the liver, which is most often caused by a virus. In the United States, the most common type of viral hepatitis | |''[[Hepatitis]]'' is inflammation of the [[liver]], which is most often caused by a virus. In the United States, the most common type of viral hepatitis is [[Hepatitis C]]. Over time, chronic [[Hepatitis C]] can lead to serious liver problems including liver damage, [[cirrhosis]], liver failure, or [[Liver tumor|liver cancer]]. [[Centers for Disease Control and Prevention|CDC]] recommends that anyone who was born between 1945 and 1965 get tested for [[Hepatitis C]]. | ||
'''Please [[Hepatitis C|click here]] to know more about ''[[Hepatitis C]]''''' | '''Please [[Hepatitis C|click here]] to know more about ''[[Hepatitis C]]''''' | ||
|} | |} |
Revision as of 18:40, 3 February 2017
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Vishal Devarkonda, M.B.B.S[2]
Overview
World wide, cancer is among the leading causes of morbidity and mortality, contributing to approximately 8.2 million deaths in 2012, with an estimated 13% of overall deaths.[1] WHO expects a 70% increase in number of new cases over the next 2 decades.[2] The burden of cancer is substantial and increasing worldwide.[3] The incidence, prevalence and mortality of a specific cancer varies widely across countries. This variability is attributable to variations in lifestyle risk factors (tobacco use, physical inactivity, excess body weight, reproductive patterns), prevalence of carcinogenic infections(Hepatitis B, Hepatitis C and HPV), genetics, and availability of health care resources.[3] In 2012, lung, prostate, colorectal, gastric, and liver carcinomas were the most common cancers among men while breast, colorectal, lung, cervical, and gastric carcinomas were common among women.[4] In 2014, Agency for healthcare research and Quality has estimated that the direct medical cost for cancer in United states were at $87.7 billion dollars.[5]It is estimated that HBV/HCV and HPV are responsible for up to 20% of cancer deaths in low and middle-income countries. It is also estimated that more then 30% of the cases can be prevented. Measures to prevent some types of cancer include effective screening, vaccination, and lifestyle modifications. In this page we discussed the epidemiology and primary care aspects in preventing cancer.
Epidemiology
World wide, cancer is among the leading causes of morbidity and mortality, contributing to approximately 8.2 million deaths in 2012, with an estimated 13% of overall deaths.[1] The most common type of cancer, excluding non-melanoma skin cancers is breast cancer, with more than 249,000 new cases expected in the United States in 2016. The next most common cancers are lung cancer and prostate cancer. In United states, to qualify as a common cancer, the estimated annual incidence for 2016 had to be 40,000 cases or more.
The following table gives the estimated numbers of new cases and deaths in Unites states for each common cancer type: [6]
American Cancer Society. Cancer Facts & Figures 2016 | ||
---|---|---|
Cancer Type | Estimated New Cases | Estimated Deaths |
Breast | 249,200 | 40,890 |
Lung (Including Bronchus) | 224,390 | 158,080 |
Prostate | 180,890 | 26,120 |
Colon and Rectal (Combined) | 134,490 | 49,190 |
Bladder | 76,960 | 16,390 |
Melanoma | 76,380 | 10,130 |
Non-Hodgkin Lymphoma | 72,580 | 20,150 |
Thyroid | 64,300 | 1,980 |
Kidney (Renal Cell and Renal Pelvis) Cancer | 62,700 | 14,240 |
Leukemia (All Types) | 60,140 | 24,400 |
Endometrial | 60,050 | 10,470 |
Pancreatic | 53,070 | 41,780 |
Adulthood cancers
Top 10 Cancer sites: 2013, Male and Female, Unites States-All Races | |||
---|---|---|---|
Incidence | Mortality | ||
Cancer type | Incidence | Cancer type | Mortality |
Female Breast | 123.7 | Lung and Bronchus | 43.4 |
Prostate | 101.6 | Female Breast | 20.7 |
Lung and Bronchus | 59.4 | Prostate | 19.2 |
Colon and rectum | 38.4 | Colon and rectum | 14.5 |
Corpus and Uterus | 25.9 | Pancreas | 10.8 |
Melanomas of the Skin | 20.7 | Ovary | 7.2 |
Urinary Bladder | 20.0 | Leukemias | 6.7 |
Non-Hodgkin Lymphoma | 18.5 | Liver and Intrahepatic Bile duct | 6.5 |
Kidney and Renal Pelvis | 16.0 | Non-Hodgkin Lymphoma | 5.7 |
Thyroid | 14.6 | Corpus and Uterus | 4.6 |
* Rates are per 100,000 persons and are age-adjusted to the 2000 U.S. standard population
Most common cancers in male and female in United States | |||||||
---|---|---|---|---|---|---|---|
Male | Female | ||||||
most common (by occurrence) | Incidence | most common (by mortality) [7] | Mortality | most common (by occurrence) | Incidence | most common (by mortality) [7] | Mortality |
Prostate cancer | 101.6 | Lung cancer | 53.9 | Breast cancer | 123.7 | Lung cancer | 35.4 |
Lung cancer | 69.8 | Prostate cancer | 19.2 | Lung cancer | 51.5 | Breast cancer | 20.7 |
Colorectal cancer | 44.2 | Colorectal cancer | 17.3 | Colorectal cancer | 33.6 | Colorectal cancer | 12.1 |
* Rates are per 100,000 persons and are age-adjusted to the 2000 U.S. standard population
Childhood Cancers
In 2013, the most commonly diagnosed cancers and leading causes of cancer death in children aged 0 to 19 years were Leukemia's and Central nervous system cancers.[8]
Childhood cancers | ||||
---|---|---|---|---|
Incidence | Mortality | |||
Cancer type | 0-14 years | 0-19 years | 0-14 years | 0-19 years |
All cancers combined | 16.8 | 18.0 | 2.1 | 2.3 |
Leukemias | 4.8 | 4.3 | 0.6 | 0.6 |
Brain and Central nervous system cancer | 3.6 | 3.2 | 0.7 | 0.7 |
* Rates are per 100,000 persons and are age-adjusted to the 2000 U.S. standard population
Please click here to know more about the cancer epidemiology
Prevention
Cancer prevention Include:
- Screening
- Vaccination
- Life style modifications
Screening
Breast Cancer
United states preventive services task force recommendations for Breast cancer screening | ||
---|---|---|
Population | Recommendation | Grade |
Women, 40 Years and Older | The USPSTF concludes that the current evidence is insufficient to assess the additional benefits and harms of clinical breast examination (CBE) beyond screening mammography in women 40 years or older. | I |
Women, Age 50-74 Years | The USPSTF recommends biennial screening mammography for women 50-74 years. | B |
Women, Before the Age of 50 Years | The decision to start regular, biennial screening mammography before the age of 50 years should be an individual one and take patient context into account, including the patient's values regarding specific benefits and harms. | C |
Women, 75 Years and Older | The USPSTF concludes that the current evidence is insufficient to assess the benefits and harms of screening mammography in women 75 years and older. | I |
Breast cancer screening relevance
Studies have reported that, for women of all age groups with an average risk, breast cancer screening was associated with a reduction in breast cancer mortality of approximately 20%, although there was an uncertainty in the quantitative estimates of outcomes for different breast cancer screening strategies in the United States.[9]
Please click here to know more about breast cancer screening
Colon cancer
United states preventive services task force recommendations for Colon cancer screening | ||
---|---|---|
Population | Recommendation | Grade |
Adults aged 50 to 75 years | The USPSTF recommends screening for colorectal cancer starting at age 50 years and continuing until age 75 years. | A |
Adults aged 76 to 85 years | The decision to screen for colorectal cancer in adults aged 76 to 85 years should be an individual one, taking into account the patient’s overall health and prior screening history.
|
C |
Colon cancer screening relevance
Studies have reported, 40% to 60% lower risk of incident colorectal cancer and mortality from colorectal cancer after screening colonoscopy.[10]
Please click here to know more about Colon cancer screening.
Cervical cancer
United states preventive services task force recommendations for Cervical cancer screening | ||
---|---|---|
Population | Recommendation | Grade |
Women 21 to 65 (Pap Smear) or 30-65 (in combo with HPV testing) | The USPSTF recommends screening for cervical cancer in women age 21 to 65 years with cytology (Pap smear) every 3 years or, for women age 30 to 65 years who want to lengthen the screening interval, screening with a combination of cytology and human papillomavirus (HPV) testing every 5 years. | A |
Cervical cancer screening relevance
Studies have reported, that in patients undergoing regular cervical cancer, approximately 70%-80% of cervical cancer deaths can be prevented.[11]
Please click here to know more about Cervical cancer screening.
Lung cancer
United states preventive services task force recommendations for Lung cancer screening | ||
---|---|---|
Population | Recommendation | Grade |
Adults Aged 55-80, with a History of Smoking | The USPSTF recommends annual screening for lung cancer with low-dose computed tomography (LDCT) in adults aged 55 to 80 years who have a 30 pack-year smoking history and currently smoke or have quit within the past 15 years. Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery. | B |
Lung caner screening relevance
National lung screen trial (nlst) a randomized controlled trial, involving 50,000 participants as demonstrated a 20% relative lung cancer mortality benefit.[12]
Please click here to know more about Lung cancer screening.
Vaccination
Vaccine | Recommendation | |
---|---|---|
HPV vaccine | Age< 15 years | Two doses of HPV vaccine at least six months apart. |
Age> 15 years |
| |
Hepatitis B vaccine |
|
HPV vaccine relevance in cancer prevention
Studies have reported, that introduction of the 4vHPV vaccine, has decreased the prevalence of HPV 6/11/16/18 cervical/vaginal infections, genital warts, low- and high-grade cytological abnormalities, CIN2, CIN3, and AIS among females in their teens and 20s.[13]
Please click here for know more about HPV vaccine.
Hepatitis B vaccine relevance in cancer prevention
Strong evidence that hepatocellular cancer (HCC) can be prevented is provided by a cluster randomized controlled trial of the immunization of 75,000 newborns with hepatitis B virus (HBV) vaccine. After a median of about 25 years of follow-up, the incidence ratio of primary liver cancer in the vaccination-at-birth group to the control group (68% of whom received catch-up vaccinations at ages 10–14 years) was 0.16 (95% confidence interval, 0.03–0.77).[14] These findings suggest that if HBV can be prevented, then much HCC can be prevented.
Please click here for know more about Hepatitis B vaccine.
Lifestyle modifications
Life style modifications | ||
---|---|---|
Avoiding Tobacco | Cigarette Smoking | Lung cancer is the leading cause of cancer death, and cigarette smoking causes almost all cases. Compared to nonsmokers, current smokers are about 25 times more likely to die from lung cancer. Smoking causes about 80% to 90% of lung cancer deaths. Smoking also causes cancer of the mouth and throat, esophagus, stomach, colon, rectum, liver, pancreas, voicebox (larynx), trachea, bronchus, kidney and renal pelvis, urinary bladder, and cervix, and causes acute myeloid leukemia.[15][16] |
Secondhand Smoke | Adults who are exposed to secondhand smoke at home or at work increase their risk of developing lung cancer by 20% to 30%. Concentrations of many cancer-causing and toxic chemicals are higher in secondhand smoke than in the smoke inhaled by smokers.
Please click here to know more about smoking cessation Please click here to know more about Lung cancer | |
Protecting Your Skin | Skin cancer is the most common kind of cancer in the United States. Exposure to ultraviolet (UV) rays from the sun and tanning beds appears to be the most important environmental factor involved with developing skin cancer. To help prevent skin cancer while still having fun outdoors, protect yourself by seeking shade, applying sunscreen, and wearing sun-protective clothing, a hat, and sunglasses.
Please click here to know more about Skin cancer | |
Limiting Alcohol Intake |
Please click here to know more about alcoholism | |
Keeping a Healthy Weight | Research has shown that being overweight or obese substantially raises a person’s risk of getting endometrial (uterine), breast, prostate, and colorectal cancers. Overweight is defined as a body mass index (BMI) of 25 to 29, and obesity is defined as a BMI of 30 or higher.
Please click here to know more about obesity management | |
Getting Tested for Hepatitis C | Hepatitis is inflammation of the liver, which is most often caused by a virus. In the United States, the most common type of viral hepatitis is Hepatitis C. Over time, chronic Hepatitis C can lead to serious liver problems including liver damage, cirrhosis, liver failure, or liver cancer. CDC recommends that anyone who was born between 1945 and 1965 get tested for Hepatitis C.
Please click here to know more about Hepatitis C |
Please click here to know more about Cancer prevention
References
- ↑ 1.0 1.1 http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
- ↑ http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
- ↑ 3.0 3.1 Torre LA, Siegel RL, Ward EM, Jemal A (2016). "Global Cancer Incidence and Mortality Rates and Trends--An Update". Cancer Epidemiol Biomarkers Prev. 25 (1): 16–27. doi:10.1158/1055-9965.EPI-15-0578. PMID 26667886.
- ↑ "Cdc".
- ↑ "Agency of health research and quality".
- ↑ American Cancer Society. Cancer Facts & Figures 2016. Atlanta: American Cancer Society; 2016
- ↑ 7.0 7.1 Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005). "Cancer statistics, 2005". CA Cancer J Clin. 55 (1): 10–30. PMID 15661684.
- ↑ [www.cdc.gov/uscs. "U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2013 Incidence and Mortality Web-based Report. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2016"] Check
|url=
value (help). - ↑ Myers ER, Moorman P, Gierisch JM, Havrilesky LJ, Grimm LJ, Ghate S; et al. (2015). "Benefits and Harms of Breast Cancer Screening: A Systematic Review". JAMA. 314 (15): 1615–34. doi:10.1001/jama.2015.13183. PMID 26501537. Review in: Ann Intern Med. 2016 Mar 15;164(6):JC26
- ↑ Brenner H, Stock C, Hoffmeister M (2014). "Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies". BMJ. 348: g2467. doi:10.1136/bmj.g2467. PMC 3980789. PMID 24922745.
- ↑ Landy R, Pesola F, Castañón A, Sasieni P (2016). "Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested case-control study". Br J Cancer. 115 (9): 1140–1146. doi:10.1038/bjc.2016.290. PMC 5117785. PMID 27632376.
- ↑ National Lung Screening Trial Research Team. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD; et al. (2011). "Reduced lung-cancer mortality with low-dose computed tomographic screening". N Engl J Med. 365 (5): 395–409. doi:10.1056/NEJMoa1102873. PMC 4356534. PMID 21714641. Review in: Ann Intern Med. 2011 Nov 15;155(10):JC5-06
- ↑ Garland SM, Kjaer SK, Muñoz N, Block SL, Brown DR, DiNubile MJ; et al. (2016). "Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience". Clin Infect Dis. 63 (4): 519–27. doi:10.1093/cid/ciw354. PMC 4967609. PMID 27230391.
- ↑ Qu C, Chen T, Fan C, Zhan Q, Wang Y, Lu J; et al. (2014). "Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: a cluster randomized controlled trial". PLoS Med. 11 (12): e1001774. doi:10.1371/journal.pmed.1001774. PMC 4280122. PMID 25549238.
- ↑ "U.S. Department of Health and Human Services. The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General, 2014".
- ↑ "International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans: Volume 100E: Personal Habits and Indoor Combustions. Lyon, France: International Agency for Research on Cancer; 2012".
- ↑ Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Bouvard V; et al. (2007). "Carcinogenicity of alcoholic beverages". Lancet Oncol. 8 (4): 292–3. PMID 17431955.